| Patents for A61P 25 - Drugs for disorders of the nervous system (183,225) |
|---|
| 05/06/2004 | WO2002022150A3 Medicament containing activated antithrombin iii |
| 05/06/2004 | US20040087800 Spirooxindole derivatives are analgesics for the treatment of chronic pain. |
| 05/06/2004 | US20040087796 Substituted carbazoles as inhibitors of spla2 |
| 05/06/2004 | US20040087795 E.g., paroxetine by sulfonating a 4-fluorophenyl-3-methylol-N-hydrocarbylpiperidine with a sulfonyl chloride; reacting with a phenol such as sesamol; oxycarbonylation of the piperidine N group with a chloroformic acid; and cleavage |
| 05/06/2004 | US20040087792 Tryptase-inhibitors |
| 05/06/2004 | US20040087791 Bis(substituted propynyl)-substituted benzenes, pyridines, pyrimidines, pyrazines, pyridines, furans and pyrroles; e.g., 3,5-bis-(3-(4-aminomethylbenzylaminocarbonyloxy)prop-1-ynyl)--1 -hydroxymethylbenzene |
| 05/06/2004 | US20040087789 Treating Alzheimer's disease, peripheral neuropathy, seizure disorder and/or diabetes |
| 05/06/2004 | US20040087784 Neuronal serine-threonine protein kinase |
| 05/06/2004 | US20040087777 Humanized antibodies that recognize beta amyloid peptide |
| 05/06/2004 | US20040087661 Treatment of CNS disorders with trans 4-3(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-N-methyl-1-napthalenamine |
| 05/06/2004 | US20040087658 Combination therapy using 1-aminocyclohexane derivatives and acetylcholinesterase inhibitors |
| 05/06/2004 | US20040087657 Treatment of neurodegenerative diseases and cancer of the brain using histone deacetylase inhibitors |
| 05/06/2004 | US20040087654 Nitric oxide synthase inhibitor phosphate salt |
| 05/06/2004 | US20040087646 2-Oxo-1-pyrrolidine derivatives, processes for preparing them and their uses |
| 05/06/2004 | US20040087641 Spiropyrazole compounds |
| 05/06/2004 | US20040087640 Administering by mouth; cyclooxygenase inhibitor; controlling particle size |
| 05/06/2004 | US20040087637 Antiserotonine agents; central nervous system disorders |
| 05/06/2004 | US20040087632 Controlling metabolism of lipids, cholesterol |
| 05/06/2004 | US20040087630 Combinations |
| 05/06/2004 | US20040087624 Analgesics; antiinflammatory agents; immunology; bone disorders; neurodegradation diseases |
| 05/06/2004 | US20040087621 N-(4-aryloxypiperidin-1-ylalkyl) cinnamic amides as ccr33 receptor antagonists |
| 05/06/2004 | US20040087616 1H-pyrazole and 1H-pyrrole-azabicyclic compounds for the treatment of disease |
| 05/06/2004 | US20040087608 Glutamic acid antagonist |
| 05/06/2004 | US20040087607 Adjust intensity of analgesics; blocking gangliosides |
| 05/06/2004 | US20040087605 N-but-3-enyl norbuprenorphine and methods of use |
| 05/06/2004 | US20040087598 2-pyridinyl-6,7,8,9-tetrahydropyrimido{1,2-a}pyrimidin-4-one and 7-pyridinyl-1,3-dihydoimidazo{1,2-a}pyrimidin-5(1h)one derivatives |
| 05/06/2004 | US20040087597 Preventives and remedies for complications of diabetes |
| 05/06/2004 | US20040087595 1-aryl- or 1-alkylsulfony-heterocyclybenzazoles as 5-hydroxytryptamine-6 ligands |
| 05/06/2004 | US20040087593 4-Piperazinyl benzenesulfonyl indoles and uses thereof |
| 05/06/2004 | US20040087590 Novel biphenyl and biphenyl-like cannabinoids |
| 05/06/2004 | US20040087588 Parp inhibitors |
| 05/06/2004 | US20040087575 Therapeutic chromone compounds |
| 05/06/2004 | US20040087573 Phenylpiperidines and phenylpyrrolidines |
| 05/06/2004 | US20040087566 Enzyme inhibitors; anticancer agents |
| 05/06/2004 | US20040087557 Treating muscle wasting with selective androgen receptor modulators |
| 05/06/2004 | US20040087552 Pyrrolidine modulators of ccr5 chemokine receptor activity |
| 05/06/2004 | US20040087548 Anticancer agents and treating immune disorders |
| 05/06/2004 | US20040087535 Administering a nitric oxide synthase gene in the form of naked dna; angiogenesis inhibitors |
| 05/06/2004 | US20040087510 Cardiovascular diseases and disorders; sustained delivery of nitric oxide |
| 05/06/2004 | US20040087508 Users for amino acid anticonvulsants |
| 05/06/2004 | US20040087487 Increasing concentration of dopamine neurotransmitter in central nervous system; using glycine-proline-glutamic acid (GPE); neural injury or disease |
| 05/06/2004 | US20040086942 Comprises peptide mimetic which competes for binding site of immunoglobulin receptor and prevents and treats allergic disorders |
| 05/06/2004 | US20040086905 Lipid-associated molecules |
| 05/06/2004 | US20040086904 Identifying modulators which suppress synthesis of secreted and/or membrane protein for prevention and treatment of allergic,inflammatory, skin, cardiovascular, nervous system and cancer disorders |
| 05/06/2004 | US20040086899 Compromises nuclelotide sequences coding polypeptides associated with elongation of fatty acid chains for treatment and prevention of skin, cardiovascular, inflammatory, gastrointestinal, respiratory system and bone disorders |
| 05/06/2004 | US20040086877 Multi-mode directi memory access controller and method |
| 05/06/2004 | US20040086585 Composition and methods for treating Alzheimer's disease and other amyloidoses |
| 05/06/2004 | US20040086570 Controlled-release dosage; therapy |
| 05/06/2004 | US20040086561 For preventing oral abuse of an oral opioid formulation |
| 05/06/2004 | US20040086505 Derived from human placenta |
| 05/06/2004 | US20040086485 Viral vector sequences in plasmid form delivered in-vivo to generate vector producing cells |
| 05/06/2004 | EP1416281A2 Assay for disease related conformation of a protein |
| 05/06/2004 | EP1416272A1 Pael receptor, cells and animal expressing pael receptor and method of screening remedy for parkinson's disease |
| 05/06/2004 | EP1416048A1 Nucleic acid participating in the formation of presenilin-2-gene exon 5-;defective splicing variant |
| 05/06/2004 | EP1415997A1 Polypeptides relating to signal transfer of advanced glycation end product receptor |
| 05/06/2004 | EP1415994A1 Retinal pigmented epithelium derived neurotrophic factor |
| 05/06/2004 | EP1415986A1 Spiro compounds |
| 05/06/2004 | EP1415983A1 5-amidino-n-(2-aminophenethyl)-hydroxybenzenesulfonamide derivative, medicinal composition containing the same, and intermediate therefor |
| 05/06/2004 | EP1415773A1 Gripper |
| 05/06/2004 | EP1415658A1 Remedies |
| 05/06/2004 | EP1415657A1 Remedies |
| 05/06/2004 | EP1415653A2 Use of progesterone or an agonist thereof for the inhibition of steroid synthesis |
| 05/06/2004 | EP1415651A1 Preventives/remedies for cholinergic neuropathy |
| 05/06/2004 | EP1415005A2 Endogenous retroviruses up-regulated in prostate cancer |
| 05/06/2004 | EP1414974A2 Butyrylcholinesterase polypeptide variants with increased catalytic efficiency and methods of use |
| 05/06/2004 | EP1414963A2 Lipid-associated molecules |
| 05/06/2004 | EP1414947A2 Multipotent stem cells from peripheral tissues and uses thereof |
| 05/06/2004 | EP1414937A1 Hops extracts, method for the production and use |
| 05/06/2004 | EP1414858A2 Single chain camelid vhh antibodies, method for their production in a mammal, and their uses |
| 05/06/2004 | EP1414849A2 Immune-modulating peptide |
| 05/06/2004 | EP1414841A1 Oligonucleotide-containing pharmacological compositions and their use |
| 05/06/2004 | EP1414837A1 Adenosine a3 receptor agonists |
| 05/06/2004 | EP1414826A1 Therapeutically useful tetracyclic ligands |
| 05/06/2004 | EP1414825A1 Thienopyrimidinediones and their use in the modulation of autoimmune disease |
| 05/06/2004 | EP1414824A1 Novel anticonvulsant derivative salts |
| 05/06/2004 | EP1414819A1 THERAPEUTIC 1H-PYRIDO 4,3-b]INDOLES |
| 05/06/2004 | EP1414817A1 Substituted isoindoles and e use thereof |
| 05/06/2004 | EP1414816A1 Stable polymorph of flibanserin, technical process for its preparation and the use thereof for preparing medicaments |
| 05/06/2004 | EP1414812A1 Hydroxamic acid derivatives |
| 05/06/2004 | EP1414810A2 1,4-disubstituted benzo-fused cycloalkyl urea compounds |
| 05/06/2004 | EP1414808A1 1,2,4-triazin-3,5-diones as gonadotropin-releasing hormone receptor (gnrh) antagonists |
| 05/06/2004 | EP1414804A1 Acylsemicarbazides and their use as cyclin dependent kinase (cdk) inhibitors |
| 05/06/2004 | EP1414802A1 Heteroarylheteroalkylamine derivatives and their use as inhibitors of nitric oxide synthase |
| 05/06/2004 | EP1414801A1 Arylamines for the treatment of conditions associated with gsk-3 |
| 05/06/2004 | EP1414798A2 Ultrashort-acting opioids for transdermal application |
| 05/06/2004 | EP1414788A1 Naphthylurea and naphthylacetamide derivatives as vanilloid receptor 1 (vr1) antagonists |
| 05/06/2004 | EP1414778A1 Novel vinyl carboxylic acid derivatives and their use as antidiabetics etc. |
| 05/06/2004 | EP1414775A2 Novel bicyclic and tricyclic cannabinoids |
| 05/06/2004 | EP1414525A2 2-(3,5-bis-trifluoromethyl-phenyl)-n-[6-(1,1-dioxo-1.lambda.6-thiomorpholin-4-yl)-4-(2-methyl or 4-fluoro-2-methyl substituted)phenyl-pyridin-3-yl]-n-methyl-isobutyramide |
| 05/06/2004 | EP1414522A2 Carbonic anhydrase inhibitors |
| 05/06/2004 | EP1414491A2 Methods of inhibiting amyloid toxicity |
| 05/06/2004 | EP1414481A2 Use of lhrh-antagonists for the improvement of t-cell mediated immunity |
| 05/06/2004 | EP1414478A2 Inhibition of neurodegeneration |
| 05/06/2004 | EP1414469A2 Formulation containing (lyso-) phosphatidylserine for the prevention and treatment of stress states in warm-blooded animals |
| 05/06/2004 | EP1414466A1 Combinations for the treatment of inflammatory disorders |
| 05/06/2004 | EP1414460A1 Process for the preparation of 2-(2-(4-(bis(4-fluorophenyl)methyl)-piperazin-1-yl)ethoxy)acetic acid derivatives or corresponding salt forms thereof and intermediates therefor |
| 05/06/2004 | EP1414459A1 Oral dosage form comprising a therapeutic agent and an adverse-effect agent |
| 05/06/2004 | EP1414458A1 Oral administration of 6-hydroxy-oxymorphone for use as an analgesic |
| 05/06/2004 | EP1414457A1 Chiral dinapsoline |
| 05/06/2004 | EP1414456A1 Phenyl derivatives as factor xa inhibitors |